Brief: Benitec Biopharma Releases Q2 2024 Results And Provides Operational Update

Benitec Biopharma

13/02/2024 15:18

Feb 13 (Reuters) - Benitec Biopharma Inc  BNTC.O :
    * BENITEC BIOPHARMA RELEASES SECOND QUARTER 2024 FINANCIAL
RESULTS
AND PROVIDES OPERATIONAL UPDATE
    * FIRST SUBJECT DOSED WITH BB-301 IN PHASE 1B/2A CLINICAL
TREATMENT STUDY (NCT06185673) IN NOVEMBER 2023
    * DATA SAFETY MONITORING BOARD REVIEW FOR FIRST SUBJECT
COMPLETED
AFTER DAY 28 STUDY VISIT
    * SECOND SUBJECT SCHEDULED TO RECEIVE BB-301 IN FEBRUARY
2024
    * INTERIM SAFETY DATA & EFFICACY DATA EXPECTED TO BECOME
AVAILABLE
FROM BB-301 PHASE 1B/2A CLINICAL TREATMENT STUDY (NCT06185673)
IN MID-2024
    * AS OF DECEMBER 31, 2023, CO HAD $20.4 MILLION IN CASH AND
CASH
EQUIVALENTS

Source text for Eikon:  ID:nGNX7S7JsT 
Further company coverage:  BNTC.O 

 ((Reuters.Briefs@thomsonreuters.com;))